跳至主要内容
临床试验/JPRN-UMIN000021987
JPRN-UMIN000021987已完成未知

Effect of Once-Weekly Teriparatide for Bisphosphonate-Resisitance Glucocorticoid-Induced Osteoporosis (TeriGo) - Effect of Once-Weekly Teriparatide for Bisphosphonate-Resisitance Glucocorticoid-Induced Osteoporosis (TeriGo)

Teikyo University School of Medicine (Hajime Kono) Toho University School of Medicine (Toshihiro Nanki)0 个研究点目标入组 150 人开始时间: 2016年4月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients whose BMD of 3 or more of lumbar spines cannot be analysed because of fracture or artificial materials. 2) Contraindication for bisphosphonate or teriparatide. 3) Patients who have received teriparatide or denosumab. 4) Patients with active infection or malignancy. 5) Age less than 20 years old. 6) Patients who is currently pregnant, breastfeeding or willing to get pregnant. 7) Patients who do not give consent to the study. 8) Patients who are judged to be inappropriate by the physician.

研究者

发起方
Teikyo University School of Medicine (Hajime Kono) Toho University School of Medicine (Toshihiro Nanki)

相似试验